Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2021

View Archived Issues

Positive topline data from pivotal phase III SKYLIGHT 1 and SKYLIGHT 2 studies of fezolinetant

Insmed reports phase I safety and PK data for treprostinil palmitil inhalation powder

First-in-human data from SAD and MAD studies of LTI-291 in healthy volunteers

MMP-14 is a potential marker of vestibular schwannomas

Valneva initiates further phase III study of chikungunya vaccine candidate VLA-1553

European Commission approves Heplisav B

Dosing begins in phase II trial of BBP-418 for limb girdle muscular dystrophy type 2i

Targeting AMPK-alpha prevents drug-induced hair cell loss and hearing loss

Study links antidepressant action to TRKB binding

China NMPA grants conditional approval to toripalimab in nasopharyngeal carcinoma

Puppet masters of the human gut

Metabolic changes are antibiotic resistance mechanism

PTGER4 as new therapeutic target to promote intestinal macrophage healing in IBD

AUT-00206 ameliorates audition symptoms tied to schizophrenia

Ascletis reports data on ASC-41 in overweight and obese subjects

Immunicum reports updated phase II data on ilixadencel in metastatic renal cell carcinoma

Bionomics reports PK data on new solid dose oral tablet formulation of BNC-210

Sanofi and GSK study adjuvanted recombinant protein-based COVID-19 vaccine candidate in phase II

DSMC recommends continuation of phase III study of VB-111 for recurrent ovarian cancer

MediWound outlines clinical development plans for MWPC-005 in nonmelanoma skin cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...